What we expect in your submission
We at EMD Serono do have a good understanding of existing technologies for antibody-drug conjugates, suitable targets and available antibodies.
We are only interested in proposals for antibodies that are available for licensing, including full IP rights and exclusive rights for the development and usage of the antibody as an antibody-drug conjugate and for diagnostic purposes.
Proposals from a wide range of academic as well as non-academic institutions, from start-ups as well as small and medium-sized enterprises (SMEs) are envisioned. You yourself do not need to have experience in antibody drug conjugate technologies, but your proposed antibody should have a good selectivity for the tumor-specific antigen/target. You also should be in the legal position to offer the antibody to us for further clinical use and development.
What to submit
Your proposal should include the following information:
- Collaboration Proposal:
a) A description and proof for the tumor specificity of the antibody/antibodies offered. You can withhold proprietary information, if necessary, but should provide enough information to us to appreciate the merits of your approach.
b) A brief discussion of capabilities and prior experience as relevant to the problem including any publications or citations, as appropriate. You should explain what you can provide and what might be required from our side. For example: “I can provide samples, but I would need you to run the testing”
- General Information:
a) Organization/Company/University name and address
b) The key contact person (including phone number and email address).
What we offer
Your proposal should contain non-confidential information only. All proposals will be evaluated and assessed in our R&D organization. If your proposal is interesting for us, we will get back to you within 4 weeks to discuss next steps towards a licensing agreement.
|This program is not open to U.S. healthcare professionals.|